Cargando…
Bevacizumab for glioblastoma
Individuals with glioblastoma are often characterized by older age, advanced neurologic manifestations at the primary stage, and unresectable tumors, and these factors are associated with poor treatment outcomes. Administration of bevacizumab (BV, Avastin(®)) promotes tumor regression and improves c...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671800/ https://www.ncbi.nlm.nih.gov/pubmed/26664126 http://dx.doi.org/10.2147/TCRM.S58289 |
_version_ | 1782404456941355008 |
---|---|
author | Narita, Yoshitaka |
author_facet | Narita, Yoshitaka |
author_sort | Narita, Yoshitaka |
collection | PubMed |
description | Individuals with glioblastoma are often characterized by older age, advanced neurologic manifestations at the primary stage, and unresectable tumors, and these factors are associated with poor treatment outcomes. Administration of bevacizumab (BV, Avastin(®)) promotes tumor regression and improves cerebral edema, and is expected to improve neurologic findings in many patients with malignant gliomas, including glioblastoma. Although the addition of BV to the conventional standard therapy (chemoradiotherapy with temozolomide) for newly diagnosed glioblastoma prolonged the progression-free survival time and the performance status of patients, it failed to extend overall survival time. However, more than 50% of glioblastoma patients show Karnofsky performance status ≤70 at initial presentation; therefore, BV should be used to improve or maintain their performance status as an initial treatment. Most of the adverse events of BV, except hypertension and proteinuria, occur as complications of glioblastoma, and explanation of the advantages and disadvantages of BV administration to patients is important. Herein, the efficacy, safety, and challenges of using BV for treating glioblastoma were reviewed. |
format | Online Article Text |
id | pubmed-4671800 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-46718002015-12-09 Bevacizumab for glioblastoma Narita, Yoshitaka Ther Clin Risk Manag Review Individuals with glioblastoma are often characterized by older age, advanced neurologic manifestations at the primary stage, and unresectable tumors, and these factors are associated with poor treatment outcomes. Administration of bevacizumab (BV, Avastin(®)) promotes tumor regression and improves cerebral edema, and is expected to improve neurologic findings in many patients with malignant gliomas, including glioblastoma. Although the addition of BV to the conventional standard therapy (chemoradiotherapy with temozolomide) for newly diagnosed glioblastoma prolonged the progression-free survival time and the performance status of patients, it failed to extend overall survival time. However, more than 50% of glioblastoma patients show Karnofsky performance status ≤70 at initial presentation; therefore, BV should be used to improve or maintain their performance status as an initial treatment. Most of the adverse events of BV, except hypertension and proteinuria, occur as complications of glioblastoma, and explanation of the advantages and disadvantages of BV administration to patients is important. Herein, the efficacy, safety, and challenges of using BV for treating glioblastoma were reviewed. Dove Medical Press 2015-12-01 /pmc/articles/PMC4671800/ /pubmed/26664126 http://dx.doi.org/10.2147/TCRM.S58289 Text en © 2015 Narita. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Narita, Yoshitaka Bevacizumab for glioblastoma |
title | Bevacizumab for glioblastoma |
title_full | Bevacizumab for glioblastoma |
title_fullStr | Bevacizumab for glioblastoma |
title_full_unstemmed | Bevacizumab for glioblastoma |
title_short | Bevacizumab for glioblastoma |
title_sort | bevacizumab for glioblastoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671800/ https://www.ncbi.nlm.nih.gov/pubmed/26664126 http://dx.doi.org/10.2147/TCRM.S58289 |
work_keys_str_mv | AT naritayoshitaka bevacizumabforglioblastoma |